How an antiviral pill could help in the fight against COVID-19 - CTV News | Canada News Media
Connect with us

Business

How an antiviral pill could help in the fight against COVID-19 – CTV News

Published

 on


Merck and Ridgeback Biotherapeutics announced on Friday early result that indicate their experimental oral antiviral drug molnupiravir might halve the risk of death or hospitalization from COVID-19.

In a news release, the company said 7.3% of 385 patients who received the antiviral were either hospitalized or died from Covid-19, compared with 14.1% of the 377 patients who received a placebo, which does nothing.

Full data from the molnupiravir trial has not yet been released, and this data has not yet been peer-reviewed or published. But Merck says it will seek authorization from the U.S. Food and Drug Administration, and if it’s granted, the drug could be the first antiviral treatment available orally to fight COVID-19.

“This is the most impactful result that I remember seeing of an orally available drug in the treatment of a respiratory pathogen, perhaps ever,” Dr. Scott Gottlieb, former commissioner of the U.S. Food and Drug Administration, told CNN’s Anderson Cooper on Friday. “I think getting an oral pill that can inhibit viral replication — that can inhibit this virus — is going to be a real game changer.”

Antiviral treatments are a type of antimicrobial — treatments which kill or otherwise inhibit the development of microorganisms such as bacteria (fought by antibiotics), fungi (fought by antifungals), or, in this case, a virus.

Some of the more familiar antivirals are those developed to treat herpes, HIV and the flu.

“Most people have heard of Tamiflu, and they’ve heard of acyclovir,” said Dr. Myron Cohen, a professor of medicine, microbiology, immunology and epidemiology at the University of North Carolina. Acyclovir is a type of antiviral used to treat chickenpox, herpes and shingles.

“We didn’t develop a ton of other antivirals,” he said.

What makes molnupiravir different

Another antiviral, remdesivir, is currently the only drug approved by the FDA for the treatment of COVID-19. Remdesivir, which is made by Gilead Sciences and sold under the name Veklury, is administered by intravenous infusion, so it’s not as simple as swallowing a pill.

And remdesivir doesn’t work for all COVID-19 patients. Studies have shown mixed results; it doesn’t seem to reduce the risk of death, but it does seem to help people feel better faster, when it’s given early in an illness.

The National Institutes of Health’s COVID-19 treatment guidelines recommend remdesivir for hospitalized COVID-19 patients who need supplemental oxygen, but the World Health Organization recommends against using it outside of clinical trials.

Molnupiravir would be simpler for patients — no IV required — and it works differently, by changing the SARS-CoV-2 virus to inhibit replication.

“It actually gets incorporated into the genetic material of the of the virus and introduces errors,” Dr. Daria Hazuda, chief science officer with MSD, Merck’s label operating outside of the U.S. and Canada, said in a briefing with the Science Media Center in the U.K. on Friday.

“So, over a number of incorporations, the errors make the virus less able to replicate.”

Dr. Mark Denison, a virologist at the Vanderbilt Institute for Infection, Immunology, and Inflammation, said the way molnupiravir works, called mutagenesis, is what separates it from remdesivir.

“The two basic mechanisms are either chain termination, which I call the delayed stop sign, or mutagenesis, which is like blowing potholes in the road as the car is driving along. It’s just damaging the genome,” he told CNN.

WHAT AN ANTIVIRAL PILL COULD MEAN FOR COVID-19

Cohen, who has previously worked on molnupiravir, said when looking at results for an antiviral drug like molnupiravir, he wants to see three things.

“Stop progression of disease, so you take them and you forget about it, right?” he said. “The second thing we’d like the pill to do, if you’re taking it for symptomatic disease, is stop long COVID, right? It’s not just ‘Don’t let me get progressed and die — don’t let me have lingering cough, lingering headache.’ “

Cohen said his third goal would be for “treatment to serve as prevention,” so someone with COVID-19 is less likely to transmit it to others.

“We’d like it to wipe out the SARS-CoV-2 replication in the nose so fast that your nose is no longer a danger to me,” he said.

Former Baltimore City Health Commissioner and CNN Medical Analyst Dr. Leana Wen told CNN on Friday that having an antiviral drug which could prevent a COVID-19 infection from becoming severe is “crucial.”

“We already have monoclonal antibodies that do this and actually are pretty effective. The problem is they require an infusion or injections. That’s really burdensome for the individual, that’s burdensome on the health care system,” she said, referring to Covid-19 treatments made by Regeneron, Eli Lilly and GlaxoSmithKline and Vir.

“It would be a total game changer if somebody, when they’re diagnosed with mild Covid, early on in their treatment are able to take a pill at home. That relieves the burden on the health care system. That also really helps the individual.”

Still, an antiviral can’t replace a vaccine.

White House COVID-19 Response Coordinator Jeff Zients said during a briefing on Friday that the best way to think of such a drug is as an additional tool, to be used alongside vaccines.

“This is a potential additional tool in our toolbox to protect people from the worst outcomes of COVID,” Zients said. “I think it’s really important to remember that vaccination, as we’ve talked about today, remains far and away our best tool against Covid-19. It can prevent you from getting COVID in the first place. And we want to prevent infections, not just wait to treat them once they happen.”

WHAT’S NEXT FOR MOLNUPIRAVIR

There’s still a lot to learn about the drug and who it might work for. The trial detailed Friday focused on adult patients who were considered high-risk for severe COVID-19, most commonly because of obesity, older age, diabetes and heart disease. None had been vaccinated against COVID-19.

Molnupiravir is also being studied as post-exposure prophylaxis — researchers are looking at whether it can prevent spread of the virus within households, after someone has been exposed but hasn’t yet tested positive.

Merck said Friday is plans to submit an application to the FDA for emergency use authorization as soon as possible, and to other regulatory bodies around the world.

In anticipation of the trial results, the company said it has been producing molnupiravir at risk, and expects to have 10 million treatment courses available by the end of the year.

Merck has already sold 1.7 million treatment courses to the US government, if it gets authorization or approval from the FDA. The company said it will offer tiered pricing to provide access around the world, and will work with generic drug manufacturers to speed availability to low- and middle-income countries.

Adblock test (Why?)



Source link

Continue Reading

Business

Telus prioritizing ‘most important customers,’ avoiding ‘unprofitable’ offers: CFO

Published

 on

 

Telus Corp. says it is avoiding offering “unprofitable” discounts as fierce competition in the Canadian telecommunications sector shows no sign of slowing down.

The company said Friday it had fewer net new customers during its third quarter compared with the same time last year, as it copes with increasingly “aggressive marketing and promotional pricing” that is prompting more customers to switch providers.

Telus said it added 347,000 net new customers, down around 14.5 per cent compared with last year. The figure includes 130,000 mobile phone subscribers and 34,000 internet customers, down 30,000 and 3,000, respectively, year-over-year.

The company reported its mobile phone churn rate — a metric measuring subscribers who cancelled their services — was 1.09 per cent in the third quarter, up from 1.03 per cent in the third quarter of 2023. That included a postpaid mobile phone churn rate of 0.90 per cent in its latest quarter.

Telus said its focus is on customer retention through its “industry-leading service and network quality, along with successful promotions and bundled offerings.”

“The customers we have are the most important customers we can get,” said chief financial officer Doug French in an interview.

“We’ve, again, just continued to focus on what matters most to our customers, from a product and customer service perspective, while not loading unprofitable customers.”

Meanwhile, Telus reported its net income attributable to common shares more than doubled during its third quarter.

The telecommunications company said it earned $280 million, up 105.9 per cent from the same three-month period in 2023. Earnings per diluted share for the quarter ended Sept. 30 was 19 cents compared with nine cents a year earlier.

It reported adjusted net income was $413 million, up 10.7 per cent year-over-year from $373 million in the same quarter last year. Operating revenue and other income for the quarter was $5.1 billion, up 1.8 per cent from the previous year.

Mobile phone average revenue per user was $58.85 in the third quarter, a decrease of $2.09 or 3.4 per cent from a year ago. Telus said the drop was attributable to customers signing up for base rate plans with lower prices, along with a decline in overage and roaming revenues.

It said customers are increasingly adopting unlimited data and Canada-U.S. plans which provide higher and more stable ARPU on a monthly basis.

“In a tough operating environment and relative to peers, we view Q3 results that were in line to slightly better than forecast as the best of the bunch,” said RBC analyst Drew McReynolds in a note.

Scotiabank analyst Maher Yaghi added that “the telecom industry in Canada remains very challenging for all players, however, Telus has been able to face these pressures” and still deliver growth.

The Big 3 telecom providers — which also include Rogers Communications Inc. and BCE Inc. — have frequently stressed that the market has grown more competitive in recent years, especially after the closing of Quebecor Inc.’s purchase of Freedom Mobile in April 2023.

Hailed as a fourth national carrier, Quebecor has invested in enhancements to Freedom’s network while offering more affordable plans as part of a set of commitments it was mandated by Ottawa to agree to.

The cost of telephone services in September was down eight per cent compared with a year earlier, according to Statistics Canada’s most recent inflation report last month.

“I think competition has been and continues to be, I’d say, quite intense in Canada, and we’ve obviously had to just manage our business the way we see fit,” said French.

Asked how long that environment could last, he said that’s out of Telus’ hands.

“What I can control, though, is how we go to market and how we lead with our products,” he said.

“I think the conditions within the market will have to adjust accordingly over time. We’ve continued to focus on digitization, continued to bring our cost structure down to compete, irrespective of the price and the current market conditions.”

Still, Canada’s telecom regulator continues to warn providers about customers facing more charges on their cellphone and internet bills.

On Tuesday, CRTC vice-president of consumer, analytics and strategy Scott Hutton called on providers to ensure they clearly inform their customers of charges such as early cancellation fees.

That followed statements from the regulator in recent weeks cautioning against rising international roaming fees and “surprise” price increases being found on their bills.

Hutton said the CRTC plans to launch public consultations in the coming weeks that will focus “on ensuring that information is clear and consistent, making it easier to compare offers and switch services or providers.”

“The CRTC is concerned with recent trends, which suggest that Canadians may not be benefiting from the full protections of our codes,” he said.

“We will continue to monitor developments and will take further action if our codes are not being followed.”

French said any initiative to boost transparency is a step in the right direction.

“I can’t say we are perfect across the board, but what I can say is we are absolutely taking it under consideration and trying to be the best at communicating with our customers,” he said.

“I think everyone looking in the mirror would say there’s room for improvement.”

This report by The Canadian Press was first published Nov. 8, 2024.

Companies in this story: (TSX:T)

Source link

Continue Reading

Business

TC Energy cuts cost estimate for Southeast Gateway pipeline project in Mexico

Published

 on

 

CALGARY – TC Energy Corp. has lowered the estimated cost of its Southeast Gateway pipeline project in Mexico.

It says it now expects the project to cost between US$3.9 billion and US$4.1 billion compared with its original estimate of US$4.5 billion.

The change came as the company reported a third-quarter profit attributable to common shareholders of C$1.46 billion or $1.40 per share compared with a loss of C$197 million or 19 cents per share in the same quarter last year.

Revenue for the quarter ended Sept. 30 totalled C$4.08 billion, up from C$3.94 billion in the third quarter of 2023.

TC Energy says its comparable earnings for its latest quarter amounted to C$1.03 per share compared with C$1.00 per share a year earlier.

The average analyst estimate had been for a profit of 95 cents per share, according to LSEG Data & Analytics.

This report by The Canadian Press was first published Nov. 7, 2024.

Companies in this story: (TSX:TRP)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

BCE reports Q3 loss on asset impairment charge, cuts revenue guidance

Published

 on

 

BCE Inc. reported a loss in its latest quarter as it recorded $2.11 billion in asset impairment charges, mainly related to Bell Media’s TV and radio properties.

The company says its net loss attributable to common shareholders amounted to $1.24 billion or $1.36 per share for the quarter ended Sept. 30 compared with a profit of $640 million or 70 cents per share a year earlier.

On an adjusted basis, BCE says it earned 75 cents per share in its latest quarter compared with an adjusted profit of 81 cents per share in the same quarter last year.

“Bell’s results for the third quarter demonstrate that we are disciplined in our pursuit of profitable growth in an intensely competitive environment,” BCE chief executive Mirko Bibic said in a statement.

“Our focus this quarter, and throughout 2024, has been to attract higher-margin subscribers and reduce costs to help offset short-term revenue impacts from sustained competitive pricing pressures, slow economic growth and a media advertising market that is in transition.”

Operating revenue for the quarter totalled $5.97 billion, down from $6.08 billion in its third quarter of 2023.

BCE also said it now expects its revenue for 2024 to fall about 1.5 per cent compared with earlier guidance for an increase of zero to four per cent.

The company says the change comes as it faces lower-than-anticipated wireless product revenue and sustained pressure on wireless prices.

BCE added 33,111 net postpaid mobile phone subscribers, down 76.8 per cent from the same period last year, which was the company’s second-best performance on the metric since 2010.

It says the drop was driven by higher customer churn — a measure of subscribers who cancelled their service — amid greater competitive activity and promotional offer intensity. BCE’s monthly churn rate for the category was 1.28 per cent, up from 1.1 per cent during its previous third quarter.

The company also saw 11.6 per cent fewer gross subscriber activations “due to more targeted promotional offers and mobile device discounting compared to last year.”

Bell’s wireless mobile phone average revenue per user was $58.26, down 3.4 per cent from $60.28 in the third quarter of the prior year.

This report by The Canadian Press was first published Nov. 7, 2024.

Companies in this story: (TSX:BCE)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version